Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK.
Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Molecules. 2022 Feb 15;27(4):1310. doi: 10.3390/molecules27041310.
Blood cancers are a type of liquid tumor which means cancer is present in the body fluid. Multiple myeloma, leukemia, and lymphoma are the three common types of blood cancers. Chemotherapy is the major therapy of blood cancers by systemic administration of anticancer agents into the blood. However, a high incidence of relapse often happens, due to the low efficiency of the anticancer agents that accumulate in the tumor site, and therefore lead to a low survival rate of patients. This indicates an urgent need for a targeted drug delivery system to improve the safety and efficacy of therapeutics for blood cancers. In this review, we describe the current targeting strategies for blood cancers and recently investigated and approved drug delivery system formulations for blood cancers. In addition, we also discuss current challenges in the application of drug delivery systems for treating blood cancers.
血液癌症是一种液体肿瘤,意味着癌症存在于体液中。多发性骨髓瘤、白血病和淋巴瘤是三种常见的血液癌症。化疗是通过将抗癌药物系统地注入血液中治疗血液癌症的主要方法。然而,由于抗癌药物在肿瘤部位的积累效率低,导致复发率很高,因此患者的生存率很低。这表明迫切需要一种靶向药物输送系统,以提高治疗血液癌症的安全性和疗效。在这篇综述中,我们描述了目前针对血液癌症的靶向策略,以及最近研究和批准的用于血液癌症的药物输送系统制剂。此外,我们还讨论了在应用药物输送系统治疗血液癌症方面目前面临的挑战。